Skip to main content
. 2014 May 5;8:431–446. doi: 10.2147/DDDT.S59523

Figure 5.

Figure 5

Change in glycosylated hemoglobin from 2-year comparative trial of linagliptin compared with glimepiride.

Notes: Data represent the per-protocol completers’ cohort (post hoc analysis).

Reprinted from The Lancet, 380(9840), Gallwitz B, Rosenstock J, Rauch T, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial, 475–483, Copyright (2012), with permission from Elsevier.44

Abbreviation: HbA1c, glycosylated hemoglobin.